Literature DB >> 23668525

Psoriasis.

Nancy Weigle1, Sarah McBane.   

Abstract

Psoriasis is a chronic inflammatory skin condition that is often associated with systemic manifestations. It affects about 2 percent of U.S. adults, and can significantly impact quality of life. The etiology includes genetic and environmental factors. Diagnosis is based on the typical erythematous, scaly skin lesions, often with additional manifestations in the nails and joints. Plaque psoriasis is the most common form. Atypical forms include guttate, pustular, erythrodermic, and inverse psoriasis. Psoriasis is associated with several comorbidities, including cardiovascular disease, lymphoma, and depression. Topical therapies such as corticosteroids, vitamin D analogs, and tazarotene are useful for treating mild to moderate psoriasis. More severe psoriasis may be treated with phototherapy, or may require systemic therapy. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe psoriasis and psoriatic arthritis, but have significant adverse effect profiles and require regular monitoring. Management of psoriasis must be individualized and may involve combinations of different medications and phototherapy.
Copyright © 2013 American Academy of Family Physicians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23668525

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  24 in total

Review 1.  Polymorphisms in miRNA genes and their involvement in autoimmune diseases susceptibility.

Authors:  Andrea Latini; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

2.  Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice.

Authors:  Igor Maricic; Huiming Sheng; Idania Marrero; Ekihiro Seki; Tatiana Kisseleva; Som Chaturvedi; Natasha Molle; Stephanie A Mathews; Bin Gao; Vipin Kumar
Journal:  Hepatology       Date:  2015-02-23       Impact factor: 17.425

3.  Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.

Authors:  Yukari Okubo; Yoshinori Umezawa; Shinya Sakurai; Naoki Hoshii; Hidemi Nakagawa
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-27

4.  Psychological Stress and Depression in Psoriasis Patients - a Dermatologist's Perspective.

Authors:  Haris Marios Rigas; Stefana Bucur; Diana Maria Ciurduc; Iuliana Elena Nita; Maria Magdalena Constantin
Journal:  Maedica (Buchar)       Date:  2019-09

5.  Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression.

Authors:  Anke Schwandt; Dominik Bergis; Albrecht Dapp; Stefan Ebner; Peter M Jehle; Stefan Köppen; Alexander Risse; Stefan Zimny; Reinhard W Holl
Journal:  J Diabetes Res       Date:  2015-08-17       Impact factor: 4.011

6.  Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function.

Authors:  Hyung-Ran Kim; Anbok Lee; Eun-Jeong Choi; Min-Pyo Hong; Jeong-Hae Kie; Woosung Lim; Hyeon Kook Lee; Byung-In Moon; Ju-Young Seoh
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

7.  Study of serum levels and skin expression of S100B protein in psoriasis.

Authors:  Samar Abdallah M Salem; Ekramy Ahmed El-Khateeb; Mervat Harvy; Hanaa Mohamed El-Sayed Emam; Wafaa Abdelaal; Reham El Nemr; Omneya Osama El-Hagry
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

Review 8.  Psoriasis and Atopic Dermatitis.

Authors:  Christopher E M Griffiths; Peter van de Kerkhof; Magdalena Czarnecka-Operacz
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-01

9.  Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.

Authors:  Shigetoshi Sano; Hiroshi Kubo; Hitomi Morishima; Ryosuke Goto; Richuan Zheng; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2018-03-22       Impact factor: 4.005

Review 10.  Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.

Authors:  Mehala Subramaniapillai; Nicole E Carmona; Carola Rong; Roger S McIntyre
Journal:  Dialogues Clin Neurosci       Date:  2017-03       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.